Net sales for Colgate-Palmolive were $5.13 billion in Q3 2025, a 2% increase from the prior-year quarter.

Organic sales increased 0.4%, including a 0.8% negative impact from lower private label pet sales having exited that non-strategic business.

“We are pleased to have delivered another quarter of net sales and organic sales growth, even in the face of slowing category growth in many markets and the negative impact from lower private label pet sales as we have exited that non-strategic business,” said Company President and CEO Noel Wallace. “As we transition to our new 2030 strategy and deploy our previously announced Strategic Growth and Productivity Program, we are well-positioned to reaccelerate growth despite uncertainty in global markets and lower worldwide category growth.”

He added that the 2030 strategy is the company’s blueprint for adapting to the challenges and capturing the opportunities of a more “complex” operating environment.

“Our organization is aligned and motivated, with particular focus around accelerating our science-based innovation and omni-channel demand generation capabilities to drive category growth and market shares,” he said. “The Strategic Growth and Productivity Program will help ensure we have the organizational structure and support we need to achieve our goals in the near term and deliver consistent compounded earnings per share growth over the long term.”

Full Year 2025 Guidance

Based on current spot rates and including the estimated impact of tariffs announced and finalized as of October 29, 2025, the Colgate-Palmolive expects net sales to be up low-single digits, including a flat to low-single-digit negative impact from foreign exchange.

The company expects organic sales growth to be 1% to 2%, roughly in line with year-to-date organic sales growth of 1.2%, versus at the low end of 2% to 4% previously. This includes an approximately 70 basis point impact from its exit from private label pet sales.